• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lung compartmentalization of inflammatory biomarkers in COVID-19-related ARDS.

作者信息

Jouan Youenn, Baranek Thomas, Si-Tahar Mustapha, Paget Christophe, Guillon Antoine

机构信息

INSERM, Centre d'Etude des Pathologies Respiratoires (CEPR), UMR 1100, Tours, France.

Faculté de Médecine de Tours, Université de Tours, Tours, France.

出版信息

Crit Care. 2021 Mar 24;25(1):120. doi: 10.1186/s13054-021-03513-9.

DOI:10.1186/s13054-021-03513-9
PMID:33761985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7988241/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efa/7988972/0fee3e4b5806/13054_2021_3513_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efa/7988972/0fee3e4b5806/13054_2021_3513_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2efa/7988972/0fee3e4b5806/13054_2021_3513_Fig1_HTML.jpg

相似文献

1
Lung compartmentalization of inflammatory biomarkers in COVID-19-related ARDS.新型冠状病毒肺炎相关急性呼吸窘迫综合征中炎症生物标志物的肺部分布
Crit Care. 2021 Mar 24;25(1):120. doi: 10.1186/s13054-021-03513-9.
2
Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome.间充质干细胞及其分泌组在治疗 SARS-CoV-2 诱导的急性呼吸窘迫综合征中的治疗潜力。
Anal Cell Pathol (Amst). 2020 Nov 20;2020:1939768. doi: 10.1155/2020/1939768. eCollection 2020.
3
Comparison of the Clinical Course of COVID-19 Pneumonia and Acute Respiratory Distress Syndrome in 2 Passengers from the Cruise Ship Diamond Princess in February 2020.2020年2月钻石公主号邮轮上两名乘客的新型冠状病毒肺炎与急性呼吸窘迫综合征临床病程比较
Am J Case Rep. 2020 Aug 19;21:e926835. doi: 10.12659/AJCR.926835.
4
Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial.多价免疫球蛋白早期治疗对 SARS-CoV-2 感染相关急性呼吸窘迫综合征的影响（ICAR 试验）：一项随机对照试验的研究方案。
Trials. 2021 Feb 28;22(1):170. doi: 10.1186/s13063-021-05118-7.
5
Severe Covid-19 disease: rather AVDS than ARDS?重症新冠病毒疾病：是急性血管内弥漫性凝血而非急性呼吸窘迫综合征？
Crit Care. 2020 Jun 11;24(1):327. doi: 10.1186/s13054-020-02972-w.
6
Δ9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression.Δ9-四氢大麻酚通过诱导免疫细胞凋亡，从而抑制细胞因子风暴，防止急性呼吸窘迫综合征导致的死亡。
Int J Mol Sci. 2020 Aug 28;21(17):6244. doi: 10.3390/ijms21176244.
7
Covid-19, Angiogenesis, and ARDS Endotypes.新型冠状病毒肺炎、血管生成与急性呼吸窘迫综合征的内型
N Engl J Med. 2020 Jul 9;383(2):182-183. doi: 10.1056/NEJMe2018629. Epub 2020 May 21.
8
Lung Mechanics in COVID-19 Resemble Respiratory Distress Syndrome, Not Acute Respiratory Distress Syndrome: Could Surfactant Be a Treatment?新型冠状病毒肺炎中的肺力学类似呼吸窘迫综合征，而非急性呼吸窘迫综合征：表面活性剂能否成为一种治疗方法？
Am J Respir Crit Care Med. 2020 Aug 15;202(4):624-626. doi: 10.1164/rccm.202004-1471LE.
9
Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.托珠单抗治疗 COVID-19 急性呼吸窘迫综合征：两例危重症患者的成功转归。
Immunotherapy. 2020 Oct;12(15):1127-1132. doi: 10.2217/imt-2020-0154. Epub 2020 Jul 14.
10
Simultaneous ventilation of two simulated ARDS patients in COVID-19 pandemic.在新冠疫情期间对两名模拟急性呼吸窘迫综合征患者进行同步通气
Crit Care. 2020 May 11;24(1):214. doi: 10.1186/s13054-020-02940-4.

引用本文的文献

1
Considering local immunity for innovative immunomodulatory approaches: pulmonary sepsis as a use case.考虑用于创新免疫调节方法的局部免疫：以肺部脓毒症为例
Front Immunol. 2025 Aug 7;16:1627313. doi: 10.3389/fimmu.2025.1627313. eCollection 2025.
2
Innate immune response in acute critical illness: a narrative review.急性危重症中的固有免疫反应：一项叙述性综述。
Ann Intensive Care. 2024 Sep 4;14(1):137. doi: 10.1186/s13613-024-01355-6.
3
A narrative review of chemokine receptors CXCR1 and CXCR2 and their role in acute respiratory distress syndrome.

本文引用的文献

1
Alveolar compartmentalization of inflammatory and immune cell biomarkers in pneumonia-related ARDS.肺炎相关性 ARDS 中炎症和免疫细胞生物标志物的肺泡区隔化。
Crit Care. 2021 Jan 9;25(1):23. doi: 10.1186/s13054-020-03427-y.
2
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.严重和危重新冠肺炎中的细胞因子升高：快速系统评价、荟萃分析，并与其他炎症综合征比较。
Lancet Respir Med. 2020 Dec;8(12):1233-1244. doi: 10.1016/S2213-2600(20)30404-5. Epub 2020 Oct 16.
3
COVID-19: more than a cytokine storm.
趋化因子受体 CXCR1 和 CXCR2 的综述及其在急性呼吸窘迫综合征中的作用。
Eur Respir Rev. 2024 Jul 24;33(173). doi: 10.1183/16000617.0172-2023. Print 2024 Jul.
4
Compartmentalization of the inflammatory response during bacterial sepsis and severe COVID-19.细菌败血症和重症 COVID-19 期间炎症反应的区室化
J Intensive Med. 2024 Feb 27;4(3):326-340. doi: 10.1016/j.jointm.2024.01.001. eCollection 2024 Jul.
5
Case study observational research: inflammatory cytokines in the bronchial epithelial lining fluid of COVID-19 patients with acute hypoxemic respiratory failure.病例对照观察性研究：新冠病毒病急性低氧性呼吸衰竭患者支气管上皮衬液中的炎性细胞因子
Crit Care. 2024 Apr 23;28(1):134. doi: 10.1186/s13054-024-04921-3.
6
Hydrocortisone rapidly and significantly reduces the IL-6 level in blood and lungs of patients with COVID-19-related ARDS.氢化可的松能迅速且显著降低新型冠状病毒肺炎相关急性呼吸窘迫综合征患者血液和肺部中的白细胞介素-6水平。
Crit Care. 2024 Mar 28;28(1):101. doi: 10.1186/s13054-024-04887-2.
7
Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients.纵向血浆蛋白质组学揭示了危重症COVID-19患者肺泡-毛细血管屏障破坏的生物标志物。
Nat Commun. 2024 Jan 25;15(1):744. doi: 10.1038/s41467-024-44986-w.
8
Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS).急性呼吸窘迫综合征（ARDS）中的信号通路和潜在治疗靶点。
Respir Res. 2024 Jan 13;25(1):30. doi: 10.1186/s12931-024-02678-5.
9
The role of trained immunity in COVID-19: Lessons for the next pandemic.训练免疫在 COVID-19 中的作用：为下一次大流行提供的教训。
Cell Host Microbe. 2023 Jun 14;31(6):890-901. doi: 10.1016/j.chom.2023.05.004.
10
Repurposing an 'Old' Drug for the Treatment of COVID-19-Related Cytokine Storm.重新利用一种“老”药治疗新冠相关细胞因子风暴。
J Clin Med. 2023 May 10;12(10):3386. doi: 10.3390/jcm12103386.
新冠病毒肺炎：不止是一场细胞因子风暴
Crit Care. 2020 Sep 4;24(1):549. doi: 10.1186/s13054-020-03267-w.
4
Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions.患有新冠肺炎及其他病症的重症患者体内的细胞因子水平
JAMA. 2020 Sep 3;324(15):1565-7. doi: 10.1001/jama.2020.17052.
5
Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome.COVID-19 急性呼吸窘迫综合征患者的失控固有和受损适应性免疫反应。
Am J Respir Crit Care Med. 2020 Dec 1;202(11):1509-1519. doi: 10.1164/rccm.202005-1885OC.
6
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients.探讨治疗 COVID-19 患者肺炎和急性呼吸窘迫综合征相关细胞因子风暴的药理学方法。
Crit Care. 2020 Jun 11;24(1):331. doi: 10.1186/s13054-020-03020-3.
7
Integrative Physiology of Pneumonia.肺炎的整体生理学
Physiol Rev. 2018 Jul 1;98(3):1417-1464. doi: 10.1152/physrev.00032.2017.
8
Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise.急性呼吸窘迫综合征的生物标志物：如何使诊断更精确。
Ann Transl Med. 2017 Jul;5(14):283. doi: 10.21037/atm.2017.06.49.